A Almirall SA
A
Avatud
SektorTervishoid
11.28 2.55
Ülevaade
Aktsiahinna muutus
24h
Min
10.86
Max
11.3
Sissetulek | -4.3M 15M |
|---|---|
Müük | -257M 291M |
P/E Sektori keskmine | 57.895 49.888 |
Aktsiakasum | 0.071 |
Dividenditootlus | 1.71 |
Kasumimarginaal | 5.258 |
Töötajad | 2,108 |
EBITDA | 135M 237M |
Dividenditootlus Sektori keskmine | 1.71% 2.38% |
|---|---|
Järgmine tulemuste avaldamine | 24. juuli 2026 |
Turukapital | -163M 2.4B |
|---|---|
Eelmine avamishind | 8.73 |
Eelmine sulgemishind | 11.28 |
Uudiste sentiment
By Acuity
50%
50%
155 / 344 Pingereas Healthcare
Almirall SA Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Almirall SA Prognoos
Sentiment
By Acuity
155 / 344 Pingereas Tervishoid
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Alla keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Almirall SA
Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
